angiotensin ii has been researched along with 2,2,5,5-tetramethyl-1-pyrrolidinyloxy-3-carboxylic acid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abe, Y; Kimura, S; Nishiyama, A; Rahman, M; Shokoji, T; Zhang, GX | 1 |
1 other study(ies) available for angiotensin ii and 2,2,5,5-tetramethyl-1-pyrrolidinyloxy-3-carboxylic acid
Article | Year |
---|---|
ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction.
Topics: Acute Disease; Adrenergic alpha-Agonists; Angiotensin II; Animals; Antioxidants; Aorta; Benzimidazoles; Biphenyl Compounds; Cyclic N-Oxides; Enzyme Activation; Heart Ventricles; Hemodynamics; Hypertension; Male; Mitogen-Activated Protein Kinases; Oxidative Stress; Phenylephrine; Prazosin; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Spin Labels; Tetrazoles; Thiobarbituric Acid Reactive Substances; Vasoconstrictor Agents | 2004 |